Pear Therapeutics was a biotechnology company that pioneered the development and commercialization of Prescription Digital Therapeutics (PDTs). These are software-based treatments designed to address a range of serious diseases, including substance use disorder, opioid use disorder, and chronic insomnia. The company achieved FDA authorization for several of its products, such as reSET®, reSET-O®, and Somryst®. Despite its innovations and early successes, Pear Therapeutics faced commercialization challenges and filed for Chapter 11 bankruptcy in April 2023. Its assets were subsequently sold, marking the end of its operations as an independent entity. The company's work laid significant groundwork for the broader field of digital therapeutics.
The Boston headquarters served as the central hub for Pear Therapeutics' research and development, clinical operations, commercial strategy, and corporate administration.
Located in a prominent commercial district, the headquarters likely featured modern office facilities designed to support a collaborative and innovative work environment for its diverse teams.
The work culture at Pear Therapeutics was reportedly dynamic and mission-driven, focused on pioneering a new class of therapeutics. Employees were often passionate about the potential of PDTs to improve patient lives, though the startup environment also came with high-pressure demands.
The Boston location was significant due to its proximity to leading academic institutions, hospitals, and a rich ecosystem of talent in the life sciences and technology sectors, which was crucial for Pear's R&D and talent acquisition.
While primarily focused on the U.S. market where its initial products received FDA authorization, Pear Therapeutics had aspirations for global expansion. They engaged in early-stage discussions and partnerships to explore market access in regions like Europe and Asia. However, these efforts did not reach full commercialization globally before the company's bankruptcy. Functions supported globally were mainly related to regulatory strategy, partnership development, and initial market assessment.
3 Post Office Square, 3rd Floor
Boston
MA
USA
Address: Specific street address not publicly available post-bankruptcy. Formerly located in the SOMA or Financial District area.
To tap into the rich technology and digital health ecosystem of the San Francisco Bay Area, fostering innovation in their software-based therapeutics.
Address: Specific street address not publicly available post-bankruptcy. Formerly located in the Research Triangle Park vicinity.
To leverage the clinical research infrastructure and talent pool in the Research Triangle Park area, supporting the development and validation of their PDTs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Pear Therapeutics' leadership includes:
Pear Therapeutics has been backed by several prominent investors over the years, including:
In the 12 months prior to its bankruptcy filing in April 2023, Pear Therapeutics saw some executive changes typical of a company navigating challenging market conditions. The most significant event was the departure of the entire executive team following the bankruptcy and asset sale. As the company ceased operations in April 2023, there have been no new hires or exits from Pear Therapeutics itself in the past 12 months from the current date (May 2024).
Discover the tools Pear Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Pear Therapeutics likely utilized common corporate email formats. As the company is no longer operational, these email addresses are inactive.
[first_initial][last]@peartherapeutics.com
Format
jdoe@peartherapeutics.com
Example
0%
Success rate
Fierce Biotech • May 26, 2023
Four companies, including Click Therapeutics, acquired the assets of bankrupt Pear Therapeutics for a total of $6.05 million. Click obtained Pear's schizophrenia and depression assets, along with its PDT discovery platform....more
Endpoints News • April 7, 2023
Pear Therapeutics filed for Chapter 11 bankruptcy protection and announced plans to sell its business or assets. The company cited challenges in securing reimbursement and market adoption for its prescription digital therapeutics....more
Fierce Biotech • January 5, 2023
Pear Therapeutics laid off 59 employees, or 22% of its workforce, as part of a restructuring plan to reduce operating expenses amid financial difficulties and challenges in the digital therapeutics market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Pear Therapeutics, are just a search away.